11.22.22 -- Leveraging Advanced Technologies To Accelerate Pharma Development

Executives from Moderna, Sanofi Pasteur, Takeda, and Catalent shared behind-the-scenes information on their respective efforts to develop a COVID-19 vaccine. While their approaches were different, the companies all adopted a collaborative mindset to arrive at a vaccine as quickly and safely as possible.

Design of experiment (DoE) is the centerpiece of analytical quality by design. A DoE assay development pipeline approach delivers optimized, robust, and rugged analytical methods ready for method qualification.

Biopharmaceuticals tend to be highly unstable. A pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage.

The biopharma industry is continuously evolving to reduce costs, increase efficiency, improve pipelines, and get products to market faster. Are you achieving optimal flexibility in your biologics development and manufacturing by effectively leveraging the most advanced technologies?